<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">To date, there are no specific effective therapies for COVID-19, but pharmacologic agents are under active investigation. Old antiviral drugs of which the pharmacokinetics and side effects are already known to have been re-evaluated in the treatment [
 <xref rid="bib0245" ref-type="bibr">[49]</xref>, 
 <xref rid="bib0250" ref-type="bibr">[50]</xref>, 
 <xref rid="bib0255" ref-type="bibr">[51]</xref>, 
 <xref rid="bib0260" ref-type="bibr">[52]</xref>, 
 <xref rid="bib0265" ref-type="bibr">[53]</xref>, 
 <xref rid="bib0270" ref-type="bibr">[54]</xref>, 
 <xref rid="bib0275" ref-type="bibr">[55]</xref>, 
 <xref rid="bib0280" ref-type="bibr">[56]</xref>, 
 <xref rid="bib0285" ref-type="bibr">[57]</xref>, 
 <xref rid="bib0290" ref-type="bibr">[58]</xref>, 
 <xref rid="bib0295" ref-type="bibr">[59]</xref>, 
 <xref rid="bib0300" ref-type="bibr">[60]</xref>]. The real dilemma is the role of the basic drugs used in cardiological comorbidities and their possible interference in worsening the prognosis.
</p>
